Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Philippe Armand, Ann Mh Janssens, Giuseppe Gritti, John Radford, John M Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, P W M Johnson, David Cunningham, John P Leonard, Scott J Rodig, Patricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M Ansell

Research output: Contribution to journalArticle

Abstract

Nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody, showed promising activity in relapsed or refractory (R/R) follicular lymphoma (FL) in a phase 1 study. We conducted a phase 2 trial to evaluate further its efficacy and safety in patients with R/R FL and to explore biomarkers of response. Patients with R/R FL and at least two prior lines of therapy, each containing a CD20 antibody or an alkylating agent, were treated with nivolumab 3 mg/kg every 2 weeks. The primary endpoint was objective response rate (ORR) assessed by independent radiologic review committee. Biomarker analyses included gene expression profiling and multiplex immunofluorescence studies of pretreatment tumor samples. A total of 92 patients were treated. After a minimum follow-up of 12 months, ORR was 4% (4/92). Median PFS was 2.2 months (95% confidence interval [CI], 1.9-3.6). Median DOR was 11 months (95% CI, 8-14). Exploratory analyses suggested that responders had significantly higher proportion of CD3+ T cells in the tumor microenvironment than non-responders, but no significant differences in PD-1 or PD-L1 expression were observed. High expression of a set of tumor-associated macrophage genes was associated with reduced PFS (hazard ratio, 3.28; 95% CI, 1.76-6.11; P = .001). The safety profile was consistent with previous reports of nivolumab. In conclusion, nivolumab monotherapy was associated with very limited activity in patients with R/R FL. Better understanding of the immune biology of this disease may facilitate the development of effective checkpoint-based strategies. This trial was registered at www.clinicaltrials.gov as #NCT02038946.

Original languageEnglish
JournalBlood
DOIs
Publication statusE-pub ahead of print - Aug 31 2020

Fingerprint Dive into the research topics of 'Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Armand, P., Janssens, A. M., Gritti, G., Radford, J., Timmerman, J. M., Pinto, A., Mercadal Vilchez, S., Johnson, P. W. M., Cunningham, D., Leonard, J. P., Rodig, S. J., Martín-Regueira, P., Sumbul, A., Samakoglu, S., Tang, H., & Ansell, S. M. (2020). Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. https://doi.org/10.1182/blood.2019004753